Based on these results, patients receiving BCMA CAR-T cell therapy and GSIs together will have a better prognosis, and to some extent, this strategy can prevent the relapse of MM due to low antigen-expressing cells. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.